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STATE-OF-THE-ART PAPER STATE-OF-THE-ART PAPERMonocytes in Atherosclerosis 1541
Angie Ghattas, Helen R. Grifﬁths, Andrew Devitt, Gregory Y. H. Lip, Eduard Shantsila
Atherosclerosis has long been identiﬁed as having an inﬂammatory component contributing
to its pathogenesis; however, available therapy primarily targets hyperlipidemia and the
prevention of thrombosis. Monocytes, as a representative of the immune system, play a major
role in the initiation, propagation, and progression of atherosclerosis from a stable to an
unstable state. In this review, the authors discuss the functional role of monocytes and their
different subpopulations in atherosclerosis, acute coronary syndrome, cardiac healing, and
recovery with critical evaluation of potential future therapeutic targets in atherosclerosis and
their complications.CLINICAL RESEARCH INTERVENTIONAL CARDIOLOGYCoronary Obstruction Following TAVI 1552Henrique B. Ribeiro, JohnG.Webb, Raj R.Makkar,Mauricio G. Cohen, Samir R. Kapadia, Susheel Kodali,
Corrado Tamburino, Marco Barbanti, Tarun Chakravarty, Hasan Jilaihawi, Jean-Michel Paradis,
Fabio S. de Brito, Jr, Sergio J. Cánovas, Asim N. Cheema, Peter P. de Jaegere, Raquel del Valle,
Paul T. L. Chiam, Raúl Moreno, Gonzalo Pradas, Marc Ruel, Jorge Salgado-Fernández,
Rogerio Sarmento-Leite, Hadi D. Toeg, James L. Velianou, Alan Zajarias, Vasilis Babaliaros,
Fernando Cura, Antonio E. Dager, Ganesh Manoharan, Stamatios Lerakis, Augusto D. Pichard,
Sam Radhakrishnan, Marco Antonio Perin, Eric Dumont, Eric Larose, Sergio G. Pasian,
Luis Nombela-Franco, Marina Urena, E. Murat Tuzcu, Martin B. Leon, Ignacio J. Amat-Santos,
Jonathon Leipsic, Josep Rodés-Cabau
The objective of this study was to evaluate characteristics, management, and clinical outcomes
of patients undergoing transcatheter aortic valve implantation (TAVI) who suffered coronary
obstruction (CO). The multicenter registry (n ¼ 6,688) included a total of 44 (0.66%)
patients who suffered symptomatic CO following TAVI. Baseline and procedural
variables associated with CO were older age, female sex, no prior CABG, the use of
balloon-expandable valve, and prior surgical aortic bioprosthesis. Mean LCA ostia height and
sinus of Valsalva diameters were lower in CO patients compared to matched controls.
Percutaneous coronary intervention was successful in 80% of cases but 12-month cumulative
mortality rate was 45%. The study revealed that symptomatic CO following TAVI was a rare
but life-threatening complication that occurred more frequently in women, in patients
receiving a balloon-expandable valve, and those with prior surgical bioprosthesis. Lower lying
coronary ostium and shallow sinus of Valsalva were associated anatomic factors, and despite
successful treatment, mortality remained very high.(continued on page A-17)
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Issam D. Moussa, Lloyd W. Klein, Binita Shah, Roxana Mehran, Michael J. Mack,
Emmanouil S. Brilakis, John P. Reilly, Gilbert Zoghbi, Elizabeth Holper, Gregg W. Stone
Post-procedure (percutaneous coronary intervention and coronary artery bypass surgery)
myocardial infarction as deﬁned by the “Universal Deﬁnition of Myocardial Infarction” is
based on cardiac troponin elevation and several additional clinical variables. In this expert
consensus document from the Society for Cardiovascular Angiography and Interventions,
the authors provide evidence to suggest that the current approach is overly sensitive and
detects myocardial necrosis not necessarily associated with adverse clinical events.
Additionally, using data from contemporary large-scale trials, they provide an alternate
deﬁnition of myocardial infarction that is linked to prognosis and thereby more clinically
relevant.
Editorial Comment: Harvey White, p. 1571CARDIOMETABOLIC RISKApolipoproteins and Events in the AIM-HIGH Trial 1575
John J. Albers, April Slee, Kevin D. O’Brien, Jennifer G. Robinson, Moti L. Kashyap,
Peter O. Kwiterovich, Jr, Ping Xu, Santica M. Marcovina
The authors examine the relationship between baseline and on-study apolipoproteins
(apo) A-1 and B and lipoprotein(a) [Lp(a)] levels and the development of subsequent
cardiovascular (CV) risk events in the AIM-HIGH (Atherothrombosis Intervention in
Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health
Outcomes) trial. Individuals with CV disease and low baseline levels of high-density
lipoprotein cholesterol were randomized to simvastatin þ placebo or simvastatin þ extended-
release niacin (ERN) with ezetimibe added, as needed, in both groups to maintain an on-
treatment low-density lipoprotein cholesterol in the range of 40 to 80 mg/dl. Results revealed
that baseline and on-study Lp(a) were predictive of CV events in both the simvastatin þ
placebo and simvastatin þ ERN groups. ERN modestly increased 1-year apo A-1 (7%),
decreased apo B (13%), decreased the apo B/apo A-1 ratio (19%), and decreased Lp(a)
(21%), but did not reduce CV events. This study showed that Lp(a) was associated with CV
risk in both treatment groups, indicating that it contributes to residual CV risk; however,
ERN did not reduce CV risk, despite favorable lipoprotein changes.(continued on page A-18)
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John R. Guyton, April E. Slee, Todd Anderson, Jerome L. Fleg, Ronald B. Goldberg,
Moti L. Kashyap, Santica M. Marcovina, Stephen D. Nash, Kevin D. O’Brien,
William S. Weintraub, Ping Xu, Xue-Qiao Zhao, William E. Boden
In this secondary analysis of the AIM-HIGH trial, the authors examine the relationship
between niacin treatment, lipoproteins, and cardiovascular (CV) outcomes. In the original
trial, 3,414 patients with established CV events, on simvastatin  ezetimibe were randomized
to extended-release (ER) niacin or placebo. These results reveal that CV outcomes were not
associated with ER niacin in any baseline group deﬁned by lipoprotein tertiles. There was,
however, a trend toward beneﬁt in patients with both the highest triglycerides and lowest
high-density lipoprotein (HDL) level. In-trial low-density lipoprotein (LDL)-cholesterol,
non–HDL-cholesterol, and total cholesterol/HDL-cholesterol ratio were positively
associated with CV events in the placebo group, but not in the ER niacin group. The authors
conclude that no group deﬁned by baseline lipoprotein tertiles did signiﬁcantly better with
combined therapy compared with control LDL-lowering therapy alone. However, a small
dyslipidemic subgroup may beneﬁt. ER niacin attenuated the expected relationship of
lipoprotein risk factor with CV events, suggesting that non-lipoprotein actions of niacin
could impact risk.HEART FAILUREEplerenone in High-Risk Patients 1585
Romain Eschalier, John J. V. McMurray, Karl Swedberg, Dirk J. van Veldhuisen, Henry Krum,
Stuart J. Pocock, Harry Shi, John Vincent, Patrick Rossignol, Faiez Zannad, Bertram Pitt,
for the EMPHASIS-HF Investigators
This study investigates the safety and efﬁcacy of eplerenone in the subgroup of patients
at high risk for hyperkalemia or worsening renal function (patients age 75 years, with
diabetes, with estimated glomerular ﬁltration rate <60 ml/min/1.73 m2, and with systolic
blood pressure less than a median of 123 mm Hg) enrolled in the EMPHASIS-HF
(A Comparison of Outcomes in Patients in New York Heart Association [NYHA] Class II
Heart Failure When Treated With Eplerenone or Placebo in Addition to Standard Heart
Failure Medicines) trial. Results revealed that in all high-risk subgroups, patients treated with
eplerenone had an increased risk of potassium >5.5 mmol/l, but not of potassium
>6.0 mmol/l, and of hospitalization for hyperkalemia or discontinuation of study medication.
Eplerenone was effective in reducing the primary composite endpoint, hospitalization for
heart failure (HF) or cardiovascular mortality, in all subgroups. The study concludes that in
patients with chronic HF and reduced ejection fraction, eplerenone was both efﬁcacious and
safe when carefully monitored, even in the subgroup at high risk for developing hyperkalemia
or worsening HF.
Editorial Comment: Bradley A. Bart, Sarah Nelson, p. 1594(continued on page A-19)
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Hind Mehel, Julius Emons, Christiane Vettel, Katrin Wittköpper, Danilo Seppelt, Matthias Dewenter,
Susanne Lutz, Samuel Sossalla, Lars S. Maier, Patrick Lechêne, Jérôme Leroy, Florence Lefebvre,
Audrey Varin, Thomas Eschenhagen, Stanley Nattel, Dobromir Dobrev, Wolfram-Hubertus Zimmermann,
Viacheslav O. Nikolaev, Grégoire Vandecasteele, Rodolphe Fischmeister, Ali El-Armouche
The authors sought to investigate whether myocardial phosphodiesterase-2 (PDE2) is altered
in heart failure (HF) and to determine PDE2-mediated effects on b-adrenoceptor (AR)
signaling in healthy and diseased cardiomyocytes. Immunoblotting and radio-enzymatic
assay were performed on myocardial tissues and/or isolated cardiomyocytes from human
and/or experimental HF. Results revealed that myocardial PDE2 expression and activity were
approximately 2-fold higher in advanced human HF. In diseased cardiomyocytes, higher
PDE2 activity could be further enhanced by stimulation of cyclic guanosine monophosphate
synthesis via nitric oxide donors, whereas speciﬁc PDE2 inhibition partially restored
beta-adrenergic receptor (b-AR) responsiveness. PDE2 overexpression in healthy
cardiomyocytes abolished the inotropic effect following acute b-AR stimulation without
affecting basal contractility. PDE2 overexpressing cardiomyocytes showed marked protection
from pathological hypertrophy. The authors conclude that PDE2 is markedly up-regulated in
failing hearts and is desensitized against acute b-AR stimulation. This may constitute an
important defense mechanism during stress.
Editorial Comment: David A. Kass, p. 1607HEART RHYTHM DISORDERSSigniﬁcance of Non-Type 1 Anterior Early Repolarization 1610Tsukasa Kamakura, Hiro Kawata, Ikutaro Nakajima, Yuko Yamada, Koji Miyamoto, Hideo Okamura,
Takashi Noda, Kazuhiro Satomi, Takeshi Aiba, Hiroshi Takaki, Naohiko Aihara, Shiro Kamakura,
Takeshi Kimura, Wataru Shimizu
The aim of this study was to investigate the signiﬁcance of non-type 1 anterior early
repolarization (NT1-AER) combined with inferolateral early repolarization syndrome
(ERS). From 84 patients with spontaneous ventricular ﬁbrillation (VF), 31 ERS patients
were divided into 2 groups: the ERS(A) group, consisting of inferolateral early repolarization
(ER) and NT1-AER (n ¼ 12); and the ERS(B) group that showed only inferolateral ER
(n ¼ 19). Clinical characteristics and outcomes were compared between ERS groups,
40 patients with type-1 Brugada syndrome (BS), and 13 patients with idiopathic VF lacking
J-wave. VF occurred during sleep or near sleep in 10 of 12 patients in the ERS(A) group and
22 of 40 patients in the BS group, and this was signiﬁcantly higher than the other groups. VF
reoccurrence was signiﬁcantly higher in the ERS(A) group (58%) and BS group (55%)
compared with other groups. The authors conclude that inferolateral ERS is comprised of
heterogeneous ER subtypes with and without NT1-AER. Coexistence of NT1-AER was a
key predictor of poor outcomes in patients with ERS.
Editorial Comment: Sami Viskin, p. 1619(continued on page A-20)
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Ana García-Álvarez, Leticia Fernández-Friera, José Manuel García-Ruiz, Mario Nuño-Ayala,
Daniel Pereda, Rodrigo Fernández-Jiménez, Gabriela Guzmán, Damián Sanchez-Quintana,
Angel Alberich-Bayarri, David Pastor-Escuredo, David Sanz-Rosa, Jaime García-Prieto,
Jesús G. Gonzalez-Mirelis, Gonzalo Pizarro, Luis Jesús Jimenez-Borreguero, Valentín Fuster,
Javier Sanz, Borja Ibáñez
The authors evaluated the ability of cardiac magnetic resonance (CMR) to monitor acute and
long-term changes in pulmonary vascular resistance (PVR) noninvasively. An experimental
study in pigs was designed to evaluate the ability of CMR to monitor: 1) an acute increase in
PVR generated by acute pulmonary embolization (n ¼ 10); 2) serial changes in PVR in
chronic pulmonary hypertension (PH) (n ¼ 22); and 3) changes in PVR during vasodilator
testing in chronic PH (n ¼ 10). The CMR studies were performed with simultaneous
hemodynamic assessment using a CMR-compatible Swan-Ganz catheter. Changes
in pulmonary artery velocity strongly and inversely correlated with acute increases in
PVR induced by pulmonary embolization (r ¼ 0.92), PVR ﬂuctuations in chronic PH
(r ¼ 0.89), and acute reduction during vasodilator testing (r ¼ 0.89). CMR-estimated
PVR showed adequate assessment with invasive PVR, and changes in both indexes correlated
strongly. The authors concluded that CMR allows for noninvasive monitoring of acute and
chronic changes in PVR and may be valuable in the noninvasive assessment of PH patients.
